

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

# **Dietary titanium dioxide particles and intestinal health**

A thesis presented in partial fulfilment of the requirements for the degree of

**Doctor of Philosophy**

in

Nutritional Science

at Massey University, Manawatū,

New Zealand.

**Sebastian Riedle**

2014



## Abstract

The purpose of this dissertation was to investigate the relationship between food-grade titanium dioxide particles and intestinal health, in particular the development of Crohn's disease after uptake of titanium dioxide particles in intestinal lymphoid tissues.

Crohn's disease is a common form of inflammatory bowel disease. It is characterised by chronic inflammation of the gastrointestinal tract and affects approximately 1 in 1,000 people. The aetiology of Crohn's disease is unclear, but both genetic and environmental factors are involved in the development of the disease.

The gene that is most commonly associated with Crohn's disease is the nucleotide-binding oligomerisation domain (*NOD*) 2 gene. The diet is one of the most likely environmental factors that have been proposed to play a role in Crohn's disease. It has been hypothesised that uptake of titanium dioxide particles, which are used as a whitening agent in processed foods, toothpaste, and pharmaceuticals, by macrophages in intestinal lymphoid tissues negatively affects intestinal health and contributes to the development of Crohn's disease.

To investigate this hypothesis, immune cell-stimulating properties of titanium dioxide were first assessed *in vitro* with macrophages derived from wild-type mice and mice with a Crohn's disease-like *Nod2* gene variant. These mouse models were also used to determine particle uptake in intestinal lymphoid tissues *in vivo* after exposure to titanium dioxide with the diet and effects of this dietary exposure on intestinal health and urine metabolites.

The results from the *in vitro* studies showed that titanium dioxide induced the release of the pro-inflammatory cytokine interleukin-1 $\beta$ . For the first time, it has been shown that accumulation of particles in intestinal lymphoid tissues was a consequence of titanium dioxide intake with the diet. However, this had no negative effects on growth performance and intestinal health of both wild-type mice and mice with a Crohn's disease-like *Nod2* gene variant. Nevertheless, differences in urine metabolite profiles between wild-type mice exposed to titanium dioxide and unexposed wild-type mice indicated that consumption of a titanium dioxide-containing diet affected the metabolism.

This dissertation forms the foundation for future studies with animal models about the relationship between titanium dioxide and intestinal health.



## Acknowledgements

Firstly, I owe my deepest gratitude to my supervisor Dist. Prof. Harjinder Singh (Riddet Institute, Massey University, Palmerston North, NZ) for taking on the responsibilities that come with supervising a PhD project and for his guidance and advice throughout the years.

Furthermore, I am most grateful for the support, guidance, and advice that I received from my co-supervisors Dr Nicole Roy and Dr Don Otter (both AgResearch, Palmerston North, NZ). Their support throughout the years was invaluable. Without their constant encouragement, openness to pursue new ideas, and valuable feedback this dissertation would not have been what it is now.

In addition, I am very thankful for the support offered by my co-supervisors Dr Laetitia Pele and Dr Jonathan Powell (both Medical Research Council Human Nutrition Research, Cambridge, UK) who laid the foundations for this PhD project through their extensive previous research in the field of dietary particles. Their knowledge, enthusiasm for the project, and advice through many e-mails and telephone conference calls was much appreciated. It was a great pleasure to meet Dr Pele and Dr Powell in person several times throughout this project to discuss the progress face-to-face and to carry out laboratory work at their institute.

Moreover, I would like to thank the people who kindly assisted me during this PhD project including Ms Kelly Armstrong, Dr Matthew Barnett, Dr Mark McCann, Mr Jason Peters, and Ms Leigh Ryan (all AgResearch, Palmerston North, NZ) for training in laboratory work, discussions, and/or help with sample collection during the animal studies; Ms Genevieve Baidon and Mr Ric Broadhurst (both AgResearch, Hamilton, NZ) for providing the animals for the studies and training in sample collection; Dr Jianyu Chen, Mr Douglas Hopcroft, and Ms Jordan Taylor (all Manawatū Microscopy and Imaging Centre, Massey University, Palmerston North, NZ) for help with and training in various microscopy techniques; Dr Nuno Faria and Ms Carolin Haas (both Medical Research Council Human Nutrition Research, Cambridge, UK) for assistance with laboratory work; Dr John Koolaard and Ms Catherine Lloyd-West (both AgResearch, Palmerston North, NZ) for advice on statistical analyses and R; Ms Denise Martin (AgResearch, Palmerston North, NZ) for administrative support; Ms Heike Schwendel (AgResearch, Palmerston North, NZ) for help during sample analysis with mass spectrometry; Mr Paul Smale (AgResearch, Mosgiel, NZ) for providing a

custom-made image analysis program; and Dr Wayne Young (AgResearch, Palmerston North, NZ) for advice on R and providing the R code for metabolomics data analysis.

Many thanks go to my colleagues and other students from the Food Nutrition & Health and the Rumen Microbiology teams at AgResearch (Palmerston North, NZ) for their friendship, help, and support throughout the years.

I would also like to thank the staff and students from the Biomineral Research team at the Medical Research Council Human Nutrition Research institute (Cambridge, UK) who always made me feel very welcome during my visits.

Last but not least, I thank my wife Sabine for her love, support, understanding and encouragement when I most needed it.

Finally, I would like to acknowledge the financial support for this project granted by the Riddet Institute, AgResearch, Nutrigenomics New Zealand, and the Medical Research Council, UK. Personally I was supported with a doctoral scholarship from Massey University and a stipend from AgResearch, for which I am very grateful.

All animal experiments that were carried out during the course of this project were in compliance with the New Zealand Animal Welfare Act 1999 and were approved by the Grasslands Ethics Committee (Palmerston North, NZ).







# Table of contents

<b>Abstract</b> .....	<b>iii</b>
<b>Acknowledgements</b> .....	<b>v</b>
<b>Table of contents</b> .....	<b>ix</b>
<b>List of figures</b> .....	<b>xvii</b>
<b>List of tables</b> .....	<b>xxiii</b>
<b>List of appendices</b> .....	<b>xxvii</b>
<b>List of abbreviations</b> .....	<b>xxix</b>
<b>Introduction</b> .....	<b>1</b>
<b>Chapter 1 Literature review</b> .....	<b>5</b>
1.1 The gastrointestinal tract and Crohn's disease.....	6
1.1.1 Structure and function of the mammalian gastrointestinal tract .....	6
1.1.2 Crohn's disease as a form of inflammatory bowel disease .....	11
1.2 The role of the microbial pattern recognition receptor NOD2 in Crohn's disease ...	14
1.2.1 Genetic susceptibility to Crohn's disease.....	14
1.2.2 Structure and function of NOD2 .....	16
1.2.3 Mouse models with <i>Nod2</i> gene modifications.....	17
1.3 Dietary particles in the gastrointestinal tract.....	19
1.3.1 Endogenous dietary particles.....	19
1.3.2 Exogenous dietary particles .....	21
1.3.3 Particle uptake across the intestinal epithelium.....	28
1.4 Effects of titanium dioxide on cultured cells, animal models, and humans .....	30
1.4.1 Effects of titanium dioxide on intestinal and macrophage-like cell lines.....	31
1.4.2 Effects of titanium dioxide on animal models after gastrointestinal exposure ...	41
1.4.3 Effects of titanium dioxide and bacterial lipopolysaccharide co-stimulation on cultured human cells .....	47
1.4.4 Effects of titanium dioxide on humans.....	52

1.5 Concluding remarks.....	54
1.5.1 Hypotheses concerning dietary particles .....	54
1.5.2 Hypothesis, aims, and structure of this dissertation .....	56
<b>Chapter 2 Exposure of cultured immune cells to titanium dioxide with or without co-stimulation with bacterial antigens .....</b>	<b>61</b>
2.1 Introduction.....	62
2.2 Hypothesis and aims.....	63
2.3 Materials and methods .....	64
2.3.1 Titanium dioxide particles.....	64
2.3.2 Animals .....	65
2.3.3 Culture of murine bone marrow-derived macrophages .....	66
2.3.4 Exposure of bone marrow-derived macrophages to titanium dioxide with or without bacterial antigens.....	67
2.3.5 Metabolic activity analysis.....	67
2.3.6 Flow cytometry analysis .....	68
2.3.7 Exposure of human peripheral blood mononuclear cells to titanium dioxide with or without bacterial antigens .....	72
2.3.8 Cytokine detection in cell culture supernatants .....	73
2.3.9 Statistical analysis .....	74
2.4 Results.....	75
2.4.1 Characterisation of food-grade titanium dioxide particles.....	75
2.4.2 Cytotoxicity of titanium dioxide .....	75
2.4.3 Phenotype and morphology of bone marrow-derived macrophages after exposure to titanium dioxide .....	79
2.4.4 Activation of bone marrow-derived macrophages after exposure to titanium dioxide.....	86
2.4.5 Cytokine secretion by bone marrow-derived macrophages after exposure to titanium dioxide .....	92

2.4.6 Cytokine secretion by human peripheral blood mononuclear cells after exposure to titanium dioxide.....	96
2.5 Discussion .....	99
2.5.1 Reassessment of the hypothesis .....	99
2.5.2 Suitability of bone marrow-derived macrophages as a model for intestinal macrophages .....	99
2.5.3 Cytotoxicity of titanium dioxide.....	100
2.5.4 Uptake of titanium dioxide by cultured cells.....	103
2.5.5 Activation marker expression after exposure to titanium dioxide .....	105
2.5.6 Pro-inflammatory cytokine secretion after exposure to titanium dioxide.....	106
2.5.7 Conclusion.....	111
<b>Chapter 3 Exposure of wild-type mice to dietary titanium dioxide.....</b>	<b>115</b>
3.1 Introduction .....	116
3.2 Hypothesis and aims .....	117
3.3 Materials and methods.....	117
3.3.1 Study considerations .....	117
3.3.2 Preparation of titanium dioxide-containing mouse diets.....	118
3.3.3 Animals and experimental design.....	121
3.3.4 Tissue collection .....	122
3.3.5 Flow cytometry analysis.....	123
3.3.6 Sample preparation for microscopy.....	127
3.3.7 Dark field microscopy.....	127
3.3.8 Haematoxylin and eosin staining and bright field microscopy .....	128
3.3.9 Reflectance confocal microscopy and image analysis .....	129
3.3.10 Immunofluorescence staining and confocal microscopy .....	130
3.3.11 Statistical analysis.....	131
3.4 Results .....	132
3.4.1 Detection of titanium dioxide particles in the diet .....	132

3.4.2 Performance and titanium dioxide intake.....	132
3.4.3 Effects of dietary titanium dioxide exposure on immune cell populations of intestinal lymphoid tissues.....	136
3.4.4 Observation of titanium dioxide particle uptake in intestinal lymphoid tissues with dark field microscopy.....	150
3.4.5 Observation of titanium dioxide particle uptake in Peyer’s patches with bright field microscopy.....	150
3.4.6 Assessment of titanium dioxide particle uptake in Peyer’s patches with reflectance confocal microscopy.....	150
3.4.7 Titanium dioxide particle uptake by Peyer’s patch dendritic cells.....	156
3.5 Discussion.....	156
3.5.1 Reassessment of the hypothesis.....	156
3.5.2 Titanium dioxide incorporation into the diet.....	162
3.5.3 Effects of oral exposure to titanium dioxide on body weights.....	162
3.5.4 Daily titanium dioxide intake in this study.....	163
3.5.5 Immune cell populations of murine Peyer’s patches.....	164
3.5.6 Titanium dioxide particle uptake in Peyer’s patches.....	165
3.5.7 Conclusion.....	167

**Chapter 4 Exposure of wild-type mice and mice with a Crohn’s disease-like *Nod2* gene variant to dietary titanium dioxide ..... 171**

4.1 Introduction.....	172
4.2 Hypothesis and aims.....	173
4.3 Materials and methods.....	173
4.3.1 Study considerations.....	173
4.3.2 Experimental design, diets, and animals.....	173
4.3.3 Tissue collection and sample preparation.....	175
4.3.4 Histology of ileum and colon.....	175
4.3.5 Dark field and reflectance confocal microscopy.....	176

4.3.6 Flow cytometry analysis.....	176
4.3.7 Statistical analysis.....	177
4.4 Results.....	178
4.4.1 Body weight and intestinal characteristics of wild-type mice and mice with a Crohn’s disease-like <i>Nod2</i> gene variant on a standard diet.....	178
4.4.2 Performance and titanium dioxide intake.....	181
4.4.3 Bright-field microscopy and histology of ileum and colon cross-sections.....	187
4.4.4 Assessment of titanium dioxide particle uptake in Peyer’s patches and the ileal mucosa.....	187
4.4.5 Monocyte populations of Peyer’s patches from wild-type mice and mice with a Crohn’s disease-like <i>Nod2</i> gene variant on a standard diet.....	197
4.5 Discussion.....	197
4.5.1 Reassessment of the hypothesis.....	197
4.5.2 Considerations about the performance of mice with a Crohn’s disease-like <i>Nod2</i> gene variant.....	197
4.5.3 Titanium dioxide particle uptake in Peyer’s patches of mice with a Crohn’s disease-like <i>Nod2</i> gene variant.....	201
4.5.4 Titanium dioxide particle uptake across the intestinal epithelium.....	203
4.5.5 Conclusion.....	204
<b>Chapter 5 Effects of dietary titanium dioxide on urine metabolite profiles of wild-type mice and mice with a Crohn’s disease-like <i>Nod2</i> gene variant.....</b>	<b>207</b>
5.1 Introduction.....	208
5.2 Hypothesis and aims.....	209
5.3 Materials and methods.....	210
5.3.1 Metabolomics analysis workflow.....	210
5.3.2 Animals and urine collection.....	210
5.3.3 Sample preparation.....	212
5.3.4 Liquid chromatography mass spectrometry analysis.....	212
5.3.5 Data analysis.....	213

5.3.6 Database searching and comparison with literature .....	215
5.4 Results.....	216
5.4.1 Urine metabolite profile comparisons of wild-type mice exposed to dietary titanium dioxide .....	216
5.4.2 Urine metabolite profile comparisons of wild-type mice and mice with a Crohn's disease-like <i>Nod2</i> gene variant exposed dietary titanium dioxide.....	221
5.4.3 Discriminant ions in urine samples from wild-type mice and mice with a Crohn's disease-like <i>Nod2</i> gene variant exposed dietary titanium dioxide.....	227
5.5 Discussion.....	239
5.5.1 Reassessment of the hypothesis.....	239
5.5.2 Considerations about the factors of the statistical analyses.....	239
5.5.3 Dietary titanium dioxide particles and tryptophan metabolism.....	240
5.5.4 Metabolomics studies of mouse models for inflammatory bowel disease .....	242
5.5.5 Conclusion .....	243
<b>Chapter 6 General discussion .....</b>	<b>245</b>
6.1 Summary of the main findings.....	246
6.2 General discussion.....	247
6.2.1 Exposure of cultured macrophages to titanium dioxide.....	247
6.2.2 Inflammasome-mediated secretion of interleukin-1 $\beta$ .....	248
6.2.3 Other cytokines and chemokines associated with Crohn's disease .....	250
6.2.4 Advantages of research with animal models .....	251
6.2.5 Limitations of mice with a Crohn's disease-like <i>Nod2</i> gene variant as a model for Crohn's disease .....	252
6.2.6 Alternative mouse models for Crohn's disease .....	253
6.3 Future perspectives.....	255
6.4 Conclusion .....	257
<b>References .....</b>	<b>261</b>
<b>Appendices .....</b>	<b>301</b>







## List of figures

<b>Figure 1.1</b> Schematic overview of the structure of the gastrointestinal tract. ....	7
<b>Figure 1.2</b> Schematic overview of the small intestine including lymphoid tissues. ....	10
<b>Figure 1.3</b> Overview of the structure of this dissertation. ....	59
<b>Figure 2.1</b> Gating strategy for flow cytometry analysis of TiO <sub>2</sub> -exposed BMDMs. ....	71
<b>Figure 2.2</b> TiO <sub>2</sub> particle characterisation. ....	76
<b>Figure 2.3</b> Metabolic activity of BMDMs after TiO <sub>2</sub> exposure with or without MDP/PGN co-stimulation. ....	77
<b>Figure 2.4</b> Viability of BMDMs after TiO <sub>2</sub> exposure with or without MDP/PGN co-stimulation. ....	81
<b>Figure 2.5</b> F4/80 expression of BMDMs after TiO <sub>2</sub> exposure with or without MDP/PGN co-stimulation. ....	82
<b>Figure 2.6</b> FSC versus SSC dot plots of TiO <sub>2</sub> -exposed BMDMs. ....	83
<b>Figure 2.7</b> FSC intensity of BMDMs after TiO <sub>2</sub> exposure with or without MDP/PGN co-stimulation. ....	85
<b>Figure 2.8</b> SSC intensity of BMDMs after TiO <sub>2</sub> exposure with or without MDP/PGN co-stimulation. ....	87
<b>Figure 2.9</b> Relative SSC increase of TiO <sub>2</sub> -exposed BMDMs compared to unstimulated controls with or without MDP/PGN co-stimulation. ....	88
<b>Figure 2.10</b> CD80 expression of BMDMs after TiO <sub>2</sub> exposure with or without MDP/PGN co-stimulation. ....	90
<b>Figure 2.11</b> CD86 expression of BMDMs after TiO <sub>2</sub> exposure with or without MDP/PGN co-stimulation. ....	91
<b>Figure 2.12</b> TNF- $\alpha$ secretion by BMDMs after TiO <sub>2</sub> exposure with or without MDP/PGN co-stimulation. ....	94
<b>Figure 2.13</b> IL-1 $\beta$ secretion by BMDMs after TiO <sub>2</sub> exposure with or without MDP/PGN co-stimulation. ....	95
<b>Figure 2.14</b> IL-1 $\beta$ secretion by PBMCs after TiO <sub>2</sub> exposure with or without MDP/PGN co-stimulation. ....	97

<b>Figure 2.15</b> IL-17 secretion by PBMCs after TiO <sub>2</sub> exposure with or without MDP/PGN co-stimulation.....	98
<b>Figure 3.1</b> Gating strategy to identify lymphocyte subsets in PPs and MLNs with flow cytometry.....	125
<b>Figure 3.2</b> Gating strategy to identify monocyte subsets and DC subpopulations in PPs and MLNs with flow cytometry. ....	126
<b>Figure 3.3</b> TiO <sub>2</sub> particles in AIN-76A diet containing 625 mg TiO <sub>2</sub> /kg. ....	133
<b>Figure 3.4</b> Body weights of WT mice fed a diet with or without TiO <sub>2</sub> for 6 weeks. ....	137
<b>Figure 3.5</b> Body weights of WT mice fed a diet with or without TiO <sub>2</sub> for 12 weeks. ....	138
<b>Figure 3.6</b> Body weights of WT mice fed a diet with or without TiO <sub>2</sub> for 18 weeks. ....	139
<b>Figure 3.7</b> Frequencies of lymphocytes and monocytes in PPs and MLNs from WT mice fed a diet with or without TiO <sub>2</sub> . ....	146
<b>Figure 3.8</b> Frequencies of lymphocyte populations in PPs and MLNs from WT mice fed a diet with or without TiO <sub>2</sub> . ....	147
<b>Figure 3.9</b> Frequencies of monocyte populations in PPs and MLNs from WT mice fed a diet with or without TiO <sub>2</sub> . ....	148
<b>Figure 3.10</b> Frequencies of DC subsets in PPs and MLNs from WT mice fed a diet with or without TiO <sub>2</sub> .....	149
<b>Figure 3.11</b> Dark field microscopy images of PP cross-sections from WT mice fed a diet with or without TiO <sub>2</sub> .....	151
<b>Figure 3.12</b> Dark field microscopy images of MLN cross-sections from WT mice fed a diet with or without TiO <sub>2</sub> . ....	152
<b>Figure 3.13</b> Bright field microscopy images of PP cross-sections from WT mice fed a diet with or without TiO <sub>2</sub> . ....	153
<b>Figure 3.14</b> Reflectance confocal microscopy images of PP cross-sections from WT mice fed a diet with or without TiO <sub>2</sub> . ....	154
<b>Figure 3.15</b> Reflectance confocal microscopy images of the SED area from a WT mouse fed a diet with TiO <sub>2</sub> . ....	155
<b>Figure 3.16</b> TiO <sub>2</sub> particle uptake in SED areas from WT mice fed a diet with or without TiO <sub>2</sub> .....	157

<b>Figure 3.17</b> Sizes of SED areas used for TiO <sub>2</sub> particle uptake assessment from WT mice fed a diet with or without TiO <sub>2</sub> .....	159
<b>Figure 3.18</b> Immunofluorescence confocal microscopy image of a PP cross-section from a WT mouse fed a diet with TiO <sub>2</sub> .....	160
<b>Figure 3.19</b> Immunofluorescence confocal microscopy image of the SED area from a mouse fed a diet with TiO <sub>2</sub> .....	161
<b>Figure 4.1</b> Body weights and numbers of PPs of WT and <i>Nod2<sup>m/m</sup></i> mice fed a standard rodent diet. ....	179
<b>Figure 4.2</b> Small intestine and colon lengths of WT and <i>Nod2<sup>m/m</sup></i> mice fed a standard rodent diet. ....	180
<b>Figure 4.3</b> Body weights and weight changes relative to initial body weight of WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks.....	183
<b>Figure 4.4</b> Numbers of PPs and small intestine and colon lengths of WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks.....	186
<b>Figure 4.5</b> Bright field microscopy images of ileum cross-sections from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks.....	188
<b>Figure 4.6</b> Bright field microscopy images of colon cross-sections from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks.....	189
<b>Figure 4.7</b> Ileum and colon histology scores of WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks.....	190
<b>Figure 4.8</b> Lengths of crypts and villi in the ileum from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks.....	191
<b>Figure 4.9</b> Lengths of crypts in the colon from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks.....	192
<b>Figure 4.10</b> Dark field microscopy images of PP cross-sections from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks.....	193
<b>Figure 4.11</b> TiO <sub>2</sub> particle uptake in SED areas from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks.....	194
<b>Figure 4.12</b> Sizes of SED areas used for TiO <sub>2</sub> particle uptake assessment from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks.....	195

<b>Figure 4.13</b> Dark field microscopy images of ileum cross-sections from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks.....	196
<b>Figure 4.14</b> Frequencies of monocytes and monocyte populations in PPs from WT and <i>Nod2<sup>m/m</sup></i> mice on a standard rodent diet. ....	198
<b>Figure 4.15</b> Frequencies of DC subsets in PPs from WT and <i>Nod2<sup>m/m</sup></i> mice on a standard rodent diet.....	199
<b>Figure 5.1</b> Overview of the workflow for metabolomics studies.....	211
<b>Figure 5.2</b> PLS-DA plots of negative and positive ion profiles detected in urine samples from WT mice fed a diet with or without TiO <sub>2</sub> analysed according to sex. ....	219
<b>Figure 5.3</b> PLS-DA plots of negative and positive ion profiles detected in urine samples from female WT mice fed a diet with or without TiO <sub>2</sub> analysed according to urine collection time point.....	220
<b>Figure 5.4</b> PLS-DA plots of negative and positive ion profiles detected in urine samples from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> analysed according to <i>Nod2</i> genotype.....	223
<b>Figure 5.5</b> PLS-DA plots of negative and positive ion profiles detected in urine samples from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> analysed according to urine collection time point.....	224
<b>Figure 5.6</b> PLS-DA plot of positive ion profiles detected in urine samples from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> analysed according to diet. ....	225
<b>Figure 5.7</b> PLS-DA plots of negative and positive ion profiles detected in urine samples from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks analysed according to <i>Nod2</i> genotype and diet. ....	226
<b>Figure 5.8</b> Overview of selected tryptophan catabolism pathways.....	233
<b>Figure 5.9</b> Comparisons of the levels for the negative ion <i>m/z</i> 204.0662 and the positive ion <i>m/z</i> 206.0811 detected in urine samples from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> .....	235
<b>Figure 5.10</b> Comparisons of the levels for the negative ion <i>m/z</i> 174.0554 and the positive ion <i>m/z</i> 176.0705 detected in urine samples from WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> . ....	236

**Figure 5.11** Comparisons of the levels for the negative ions  $m/z$  204.0297 and  $m/z$  160.0408 and the positive ion  $m/z$  206.0447 detected in urine samples from WT and  $Nod2^{m/m}$  mice fed a diet with or without  $TiO_2$ . .....238



## List of tables

<b>Table 1.1</b> Confectionery and other foodstuffs with TiO <sub>2</sub> available in New Zealand supermarkets.....	24
<b>Table 1.2</b> Mayonnaises and white dressings with (highlighted in red) or without TiO <sub>2</sub> available in New Zealand supermarkets.....	25
<b>Table 1.3</b> Toothpastes with (highlighted in red) or without TiO <sub>2</sub> available in New Zealand supermarkets. ....	27
<b>Table 1.4</b> Summary of studies that investigated effects of TiO <sub>2</sub> particles on cultured human cell lines. ....	32
<b>Table 1.5</b> Summary of studies that investigated effects of TiO <sub>2</sub> particles on cultured murine cell lines.....	35
<b>Table 1.6</b> Studies that investigated TiO <sub>2</sub> particle exposure on intestinal and phagocytic cell lines and their reported effects.....	40
<b>Table 1.7</b> Summary of studies that investigated effects of TiO <sub>2</sub> particles on animals. ....	42
<b>Table 1.8</b> Summary of studies that investigated effects of TiO <sub>2</sub> particles with LPS co-stimulation on cultured human cells.....	48
<b>Table 2.1</b> Two-way ANOVA results for metabolic activity comparison of murine BMDMs exposed to TiO <sub>2</sub> with or without MDP/PGN co-stimulation. ....	78
<b>Table 2.2</b> Two-way ANOVA results for viability and F4/80 expression comparison of murine BMDMs exposed to TiO <sub>2</sub> with or without MDP/PGN co-stimulation. ....	80
<b>Table 2.3</b> Two-way ANOVA results for FSC and SSC intensities and relative SSC increase comparison of murine BMDMs exposed to TiO <sub>2</sub> with or without MDP/PGN co-stimulation. ....	84
<b>Table 2.4</b> Two-way ANOVA results for CD80 and CD86 expression comparison of murine BMDMs exposed to TiO <sub>2</sub> with or without MDP/PGN co-stimulation. ....	89
<b>Table 2.5</b> Two-way ANOVA results for IL-1 $\beta$ and TNF- $\alpha$ secretion comparison of murine BMDMs exposed to TiO <sub>2</sub> with or without MDP/PGN co-stimulation. ....	93
<b>Table 3.1</b> Diet compositions according to the manufacturer. ....	120
<b>Table 3.2</b> Means ( $\pm$ SD) for age, initial and final body weights, daily weight gain, and daily food intake of female WT mice fed a diet with or without TiO <sub>2</sub> . ....	134



<b>Table 3.3</b> Means ( $\pm$ SD) for age, initial and final body weight, daily weight gain, and daily food intake of male WT mice fed a diet with or without TiO <sub>2</sub> . .....	135
<b>Table 3.4</b> Means ( $\pm$ SD) for daily TiO <sub>2</sub> intake and daily TiO <sub>2</sub> dose of female WT mice fed a diet with TiO <sub>2</sub> . .....	140
<b>Table 3.5</b> Means ( $\pm$ SD) for daily TiO <sub>2</sub> intake and daily TiO <sub>2</sub> dose of male WT mice fed a diet with TiO <sub>2</sub> . .....	141
<b>Table 3.6</b> Two-way ANOVA results for comparisons of immune cell population frequencies in PPs and MLNs of WT mice fed a diet with or without TiO <sub>2</sub> . .....	142
<b>Table 3.7</b> Mean ( $\pm$ SD) frequencies of lymphocytes and lymphocyte populations in PPs and MLNs from WT mice according to sampling time point. ....	144
<b>Table 3.8</b> Mean ( $\pm$ SD) frequencies of monocytes, monocyte populations, and DC subsets in PPs from WT mice according to sampling time point. ....	145
<b>Table 3.9</b> P-value results for pairwise group mean comparisons of the number of TiO <sub>2</sub> particles in SED areas with Tukey's HSD test. ....	158
<b>Table 4.1</b> Means ( $\pm$ SD) for age, initial and final body weight, body weight change, daily weight gain, and daily food intake of female WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> . .....	182
<b>Table 4.2</b> Means ( $\pm$ SD) for daily TiO <sub>2</sub> intake and daily TiO <sub>2</sub> dose of female WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with 625 mg TiO <sub>2</sub> /kg. ....	184
<b>Table 4.3</b> Two-way ANOVA results for comparisons of intestinal parameters of female WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> . .....	185
<b>Table 5.1</b> Number of urine samples per respective group collected from mice for metabolomics studies at different time points. ....	217
<b>Table 5.2</b> MANOVA results for comparisons of urine metabolite profiles from WT mice fed a diet with or without TiO <sub>2</sub> . .....	218
<b>Table 5.3</b> MANOVA results for comparisons of urine metabolite profiles from female WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> . .....	222
<b>Table 5.4</b> Significantly different negative discriminant ions in urine samples from female WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks and pairwise group comparisons. ....	228

<b>Table 5.5</b> Significantly different positive discriminant ions in urine samples from female WT and <i>Nod2<sup>m/m</sup></i> mice fed a diet with or without TiO <sub>2</sub> for 18 weeks and pairwise group comparisons. ....	229
<b>Table 5.6</b> Results of the METLIN database queries for potential metabolites of negative discriminant ions. ....	230
<b>Table 5.7</b> Results of the METLIN database queries for potential metabolites of positive discriminant ions. ....	231
<b>Table 5.8</b> Significantly different metabolites identified in studies comparing urine samples from CD patients and healthy controls, <i>I10<sup>-/-</sup></i> mice with intestinal inflammation and healthy WT control mice, or rats orally exposed to TiO <sub>2</sub> and unexposed rats. ....	232



## List of appendices

<b>Appendix A</b>	Normality and variance equality analysis <i>Chapter 2</i> .....	301
<b>Appendix B</b>	Average number of bone marrow cells per mouse .....	305
<b>Appendix C</b>	Normality and variance equality analysis <i>Chapter 3</i> .....	307
<b>Appendix D</b>	Normality and variance equality analysis <i>Chapter 4</i> .....	313
<b>Appendix E</b>	R code for metabolomics data analysis .....	315
<b>Appendix F</b>	R code for statistical analysis of metabolomics data .....	317



## List of abbreviations

[M+H] <sup>+</sup>	Positive molecular ion
[M-H] <sup>-</sup>	Negative molecular ion
1,007fs	Frameshift mutation at amino acid position 1,007
A5	Annexin-V
AIN	American Institute of Nutrition
ANOVA	Analysis of variance
APC	Antigen presenting cell
ASC	Apoptosis-associated speck-like protein containing a CARD
<i>ATG16L1</i>	Autophagy-related 16-like 1 gene
B cell	Bursa-derived cell
BMDC	Bone marrow-derived DC
BMDM	Bone marrow-derived macrophage
CARD	Caspase recruitment domain
CCL	CC chemokine ligand
CD	Crohn's disease
CD[number]	Cluster of differentiation [number]
CX <sub>3</sub> CR	CX <sub>3</sub> C chemokine receptor
DAPI	4',6-Diamidino-2-phenylindole
DC	Dendritic cell
DNA	Deoxyribonucleic acid
DSS	Dextran sodium sulphate
EDS	Energy-dispersive X-ray spectroscopy
ELISA	Enzyme-linked immunosorbent assay
FACS	Fluorescence-activated cell sorting
FAE	Follicle-associated epithelium
FBS	Foetal bovine serum
FDR	False discovery rate
FSC	Forward scatter
GALT	Gut-associated lymphoid tissue
GC-MS	Gas chromatography mass spectrometry
H&E	Haematoxylin and eosin
HSD	Honest significant difference

IBD	Inflammatory bowel disease
IFN	Interferon
IFR	Interfollicular region
Ig	Immunoglobulin
IL	Interleukin
<i>Il10</i> <sup>-/-</sup>	<i>Il10</i> gene-deficient
<i>IL12B</i>	IL-12 p40 subunit-encoding gene
IL-1Ra	IL-1 receptor antagonist
ILF	Isolated lymphoid follicle
I $\kappa$ B	Inhibitor of NF- $\kappa$ B
LC-MS	Liquid chromatography mass spectrometry
LP	Lamina propria
LPMC	LP mononuclear cell
LPS	Lipopolysaccharide
M cell	Microfold cell
<i>m/z</i>	Mass-to-charge
MANOVA	Multivariate ANOVA
MCP	Monocyte chemotactic protein
MDP	Muramyl dipeptide
MFI	Median fluorescence intensity
MIP	Macrophage inflammatory protein
MLN	Mesenteric lymph node
mRNA	Messenger ribonucleic acid
NF	Nuclear factor
NLR	NOD-like receptor
NLRP	NOD, leucine-rich repeats domain, and pyrin domain
NMR	Nuclear magnetic resonance spectroscopy
NOD	Nucleotide-binding oligomerisation domain
<i>NOD2</i>	<i>NOD2</i> gene (human)
<i>NOD2</i>	<i>NOD2</i> protein (human)
<i>Nod2</i>	<i>Nod2</i> gene (mouse)
<i>Nod2</i>	<i>Nod2</i> protein (mouse)
<i>Nod2</i> <sup>-/-</sup>	<i>Nod2</i> gene-deficient
<i>Nod2</i> <sup>m/m</sup>	<i>Nod2</i> gene mutation

NTA	Nanoparticle tracking analysis
$p$	Probability
PBMC	Peripheral blood mononuclear cell
PBS	Phosphate-buffered saline
PGN	Peptidoglycan
PI	Propidium iodide
PLS-DA	Partial least squares discriminant analysis
PMT	Photomultiplier tube
PP	Peyer's patch
PRR	Pattern recognition receptor
RIP	Receptor-interacting protein
ROS	Reactive oxygen species
RPMI	Roswell Park Memorial Institute
SD	Standard deviation
SED	Subepithelial dome
SEM	Scanning electron microscopy
SNP	Single nucleotide polymorphism
SSC	Side scatter
T cell	Thymus-derived cell
TCM	Tissue culture medium
TEM	Transmission electron microscopy
TGF	Transforming growth factor
Th	T helper
TiO <sub>2</sub>	Titanium dioxide
TLR	Toll-like receptor
TNBS	2,4,6-Trinitrobenzenesulfonic acid
TNF	Tumour necrosis factor
UC	Ulcerative colitis
WST	Water-soluble tetrazolium salt
WT	Wild-type



